ipharmacenter Consulting services

Keytruda and Welireg Combination Cuts Risk of RCC Recurrence by 28% in Adjuvant Setting Merck reported new Phase 3 results from the LITESPARK-022 trial showing that adding Welireg (belzutifan) to Keytruda (pembrolizumab) as adjuvant therapy significantly reduced the likelihood of recurrence or death in certain patients with clear cell renal cell carcinoma (RCC) following nephrectomy. The study demonstrated a 28% lower risk of disease recurrence or death compared with Keytruda

Eli Lilly announced FDA approval for a label expansion of tirzepatide, last year's most prescribed obesity therapy, to include a multi-dose prefilled pen delivering four weekly doses in one single-patient device. This format expands patient options alongside single-dose vials, both accessible via self-pay through LillyDirect at starting prices of $299 per month for the 2.5 mg dose, reflecting a strategic push to meet surging demand amid GLP-1 market dominance. Delivery Innova